Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RTRX

Travere Therapeutics (RTRX) Stock Price, News & Analysis

Travere Therapeutics logo

About Travere Therapeutics Stock (NASDAQ:RTRX)

Advanced Chart

Key Stats

Today's Range
$14.84
$15.09
50-Day Range
$24.25
$28.18
52-Week Range
$8.98
$24.96
Volume
663,493 shs
Average Volume
412,277 shs
Market Capitalization
$766.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RTRX Stock News Headlines

Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
Travere Therapeutics price target lowered to $30 from $32 at Scotiabank
See More Headlines

RTRX Stock Analysis - Frequently Asked Questions

Travere Therapeutics, Inc. (NASDAQ:RTRX) announced its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include CVS Health (CVS), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Novavax (NVAX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX) and Intercept Pharmaceuticals (ICPT).

Company Calendar

Last Earnings
11/05/2020
Today
7/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RTRX
Fax
N/A
Employees
221
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$146.43 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$175.34 million
Price / Cash Flow
N/A
Book Value
$5.15 per share
Price / Book
2.91

Miscellaneous

Free Float
N/A
Market Cap
$766.29 million
Optionable
Not Optionable
Beta
0.67
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:RTRX) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners